Positive results for Novo’s Xultophy
The insulin degludec and liraglutide combination helps patients achieve blood glucose targets.
Read More
Tag: Xultophy
Europe expands use of diabetes drug Xultophy
The European Commission has approved the expanded use of Novo Nordisk’s once-daily jab Xultophy in adults with type II diabetes and moderate renal impairment.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
